Botanical supplements stand at the crossroads of tradition and modernity, embodying centuries of herbal medicine practices while embracing the latest scientific advancements. As an indispensable part of global healthcare, they offer an affordable and accessible solution [1] with nearly 80% of the world's population seeking natural health benefits [2]. With the botanical supplements market expected to reach an astounding USD 70+ billion by 2028 [3], it's clear these natural remedies are more than a trend—they're a significant commercial opportunity grounded in the pursuit of wellness.
Ensuring Product Integrity in the Booming Botanical Market
The burgeoning demand for botanical supplements has catalyzed the development of innovative tools and methodologies aimed at ensuring botanical product integrity (BPI) [2]. From botanical examination to chemical profiling and bioactivity assessment, these techniques encompass a wide range of scientific disciplines. Yet, despite these advances, the industry faces challenges in fully identifying bioactive constituents and potential contaminants within botanicals [4-6], underscoring the need for new technologies capable of providing comprehensive data for BPI evaluation.
As we look at the vast array of botanical supplements available today, one thing becomes clear: the industry lacks the necessary biological standardization that would enable consumers to discern which products truly deliver physiological benefits. This lack of clarity not only undermines consumer confidence but also impedes the scientific community’s ability to provide robust recommendations.
Addressing the Challenge of Demonstrating Physiological Activity
The botanical supplement industry has witnessed a staggering growth since the Dietary Supplement Health and Education Act (DSHEA) [7] was introduced in 1994. From a modest count of around 4,000 products, the market has exploded to over 95,000 products by 2023 [8]. This rapid expansion, however, has not been matched by the development of physiological data to validate these products, leading to a critical gap in the assurance of their efficacy and safety.
A critical hurdle in botanical supplement validation is the assurance of their physiological activity. Traditional cell-based assays and rodent models, although useful, either lack the physiological relevance [9, 10] or the high throughput capability required for comprehensive assessment. The call for alternative models that can bridge the gap between laboratory tests and real-world efficacy has never been louder.
The Role of C. elegans in Bridging the Research Gap
Enter C. elegans, a microscopic worm that offers a promising solution to the industry's challenges [11]. With its quick lifecycle, large offspring number [12], and significant genetic overlap with humans [13], C. elegans serves as a powerful in vivo model for physiological data collection. This organism's contributions to science, including several Nobel Prize-winning discoveries [14, 15, 16], highlight its potential to revolutionize botanical supplement research by enabling whole-life physiological profiling in a matter of weeks.
Revolutionizing Botanical Supplement Standardization with NemaLife’s Innovation
As the dietary supplement industry continues to expand, the absence of physiological data and biological standardization becomes increasingly evident. NemaLife's organism-on-chip platform [17] utilizing C. elegans, microfluidics, and AI technology aims to address these gaps. This platform promises to establish a new toolbox for chemical profiling, assure bioequivalence and product consistency, and uncover the bioactive constituents and mechanisms of action of botanicals.
NemaLife’s Pioneering Technologies:
• Microfluidics for Hassle-Free Worm Culture: Traditional C. elegans assays, often cumbersome and labor-intensive, are transformed by NemaLife’s patented microfluidic device [17]. This innovation enables automated feeding and progeny removal, providing a controlled environment for accurate exposure assessment.
• AI-Driven Phenotypic Data Analysis with NemaStudio.ai™: Manual phenotype scoring [18, 19], a significant bottleneck in high-throughput screening, is revolutionized by NemaStudio.ai™. This AI engine automates the detection and scoring of multiple phenotypic readouts, facilitating rapid, scalable analysis of botanical efficacy and safety.
The Comprehensive Approach to Botanical Product Integrity
By integrating chemical and physiological profiling, NemaLife not only addresses the immediate needs of the botanical supplement industry but also paves the way for a new era of product standardization. This holistic approach promises to enhance our understanding of botanicals, ensuring consumers receive products of the highest integrity and efficacy.
In summary, as we navigate the intersection of ancient herbal wisdom and contemporary scientific innovation, NemaLife’s pioneering work heralds a promising future for botanical supplements. By leveraging the unique capabilities of C. elegans within an advanced technological framework, NemaLife is set to redefine the standards of natural health products, ensuring they meet the rigorous demands of modern consumers seeking safe, effective, and scientifically validated supplements.
References:
Patwardhan, B., et al., Evidence-Based Traditional Medicine for Transforming Global Health and Well-Being. J Integr Complement Med, 2023. 29(9): p. 527-530.
Khan, I.A. and T. Smillie, Implementing a "quality by design" approach to assure the safety and integrity of botanical dietary supplements. J Nat Prod, 2012. 75(9): p. 1665-73.
Botanical Supplements Market by Fortune Business Insights (https://www.fortunebusinessinsights.com/botanical-supplements-market-106514). 2022 Feb 14, 2024].
Cardellina, J.H., 2nd, Challenges and opportunities confronting the botanical dietary supplement industry. J Nat Prod, 2002. 65(7): p. 1073-84.
Shipkowski, K.A., et al., Naturally complex: Perspectives and challenges associated with Botanical Dietary Supplement Safety assessment. Food Chem Toxicol, 2018. 118: p. 963-971.
Roberts, G.K., et al., Finding the bad actor: Challenges in identifying toxic constituents in botanical dietary supplements. Food Chem Toxicol, 2019. 124: p. 431-438.
Dietary Supplement Health and Education Act of 1994 Public Law 103-417, 103rd Congress. 1994; Available from: https://ods.od.nih.gov/About/DSHEA_Wording.aspx.
Welch, C., FDA makes the case for dietary supplement product listing requirement. 2023.
Agarwal, A., et al., Use of in vitro bioassays for assessing botanicals. Curr Opin Biotechnol, 2014. 25: p. 39-44.
Prinsloo, G., et al., In vitro bioassays to evaluate beneficial and adverse health effects of botanicals: promises and pitfalls. Drug Discov Today, 2017. 22(8): p. 1187-1200.
Brenner, S., The genetics of Caenorhabditis elegans. Genetics, 1974. 77(1): p. 71-94.
Corsi, A.K., B. Wightman, and M. Chalfie, A Transparent Window into Biology: A Primer on Caenorhabditis elegans. Genetics, 2015. 200(2): p. 387-407.
Kaletta, T. and M.O. Hengartner, Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov, 2006. 5(5): p. 387-98.
Conradt, B. and H.R. Horvitz, The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell, 1998. 93(4): p. 519-29.
Chalfie, M., et al., Green fluorescent protein as a marker for gene expression. Science, 1994. 263(5148): p. 802-5.
Fire, A., et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998. 391(6669): p. 806-11.
Rahman, M., et al., NemaLife chip: a micropillar-based microfluidic culture device optimized for aging studies in crawling C. elegans. Sci Rep, 2020. 10(1): p. 16190.
Kinser, H.E. and Z. Pincus, High-throughput screening in the C. elegans nervous system. Mol Cell Neurosci, 2017. 80: p. 192-197.
Cornaglia, M., T. Lehnert, and M.A.M. Gijs, Microfluidic systems for high-throughput and high-content screening using the nematode Caenorhabditis elegans. Lab Chip, 2017. 17(22): p. 3736-3759.
Comments